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Persistent pulmonary hypertension of the newborn (PPHN) is
a syndrome of failed circulatory adaptation at birth, charac-
terized by high pulmonary vascular resistance causing ex-
trapulmonary left-to-right shunting of blood across the
ductus arteriosus and/or foramen ovale.1 Selective pulmo-
nary vasodilatation with inhaled nitric oxide (iNO) has been
proven to improve oxygenation in term newborns with
severe hypoxemic respiratory failure (HRF) and PPHN.2,3
Randomized controlled trials have demonstrated that iNO
significantly decreased the need for extracorporeal mem-
brane oxygenation in newborns greater than 34 weeks'
gestational age with HRF.4,5 Traditionally, iNO has been
delivered to intubated and mechanically ventilated babies
when they continue to be hypoxemic despite administration
of high levels of inspired oxygen. Infants with PPHN suffer
from long-term morbidity such as chronic lung disease,
neurological morbidity, and sensorineural deafness.6 Some
of these long-term consequences may be secondary to me-
chanical ventilation. The use of iNO administered by a nonin-
vasive method like nasal cannula has been only anecdotally
described, usually during the weaning process after
the neonate has been mechanically ventilated.7 We report
a case of idiopathic PPHN treated successfully with iNO
delivered through a nasal cannula, avoiding mechanical
ventilation.
Case Report
A female infant weighing 2994 g was born at 39 weeks'
gestation by spontaneous vaginal delivery to a 16-year-old
primigravida. Her antenatal history was unremarkable. There
was no history of any medication intake and no history of
infections. There were no inherited disorders reported in the
family and no history of alcohol, drugs, or cigarette smoking.
The baby was born after rupture of membranes for 6 hours
through meconium-stained amniotic fluid with Apgar scores
of 9 and 9 at 1 and 5minutes, respectively. Shewas vigorous at
birth, received routine care at delivery, andwas transferred to
the well baby nursery.
She remained asymptomatic for the next 36 hours, when
during a feed she was noted to be gray and tachypneic with a
respiratory rate of 70/min. Her oxygen saturations were
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Abstract We report a case study of a term neonate presenting with oxygen desaturation without
respiratory distress or acidosis, despite receiving 100% oxygen through a nasal cannula.
Echocardiogram showed evidence of persistent pulmonary hypertension of the new-
born (PPHN). She was successfully treated with inhaled nitric oxide (iNO) via nasal
cannula without requiring mechanical ventilation. In a term neonate with idiopathic
PPHN with adequate respiratory drive without any parenchymal lung disease, noninva-
sive methods of iNO delivery may treat the condition without the complications
associated with mechanical ventilation.
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noted to be 79 to 80% with a loud systolic murmur heard over
the left heart border, which had not been previously docu-
mented. She had an arterial blood gas with a pH of 7.38, Paco2
of 44 mm Hg and a partial pressure of oxygen (Po2) of 47 mm
Hg on 40% oxygen with an A-a gradient of 182 mm Hg. A
hyperoxia test in 100% oxygen raised her Po2 to 372 mm Hg.
A chest X-ray showed clear lung fields with no significant
abnormality (►Fig. 1). An echocardiogram revealedmoderate
tricuspid regurgitation (estimated right ventricular systolic
pressure 90 mm Hg; ►Fig. 2). Pulmonary venous return
appeared normal to the left atrium without any evidence of
obstruction. The ductus arteriosus was not visualized. The
baby was maintaining oxygen saturations of 90% in room air,
but was tachypneic with respiratory rates of 70 to 80/min.
Intermittent periods of desaturationwere observed requiring
escalation of inspired oxygen concentration to 100%. Oxygen
saturations continued to drop below 90% periodically, despite
receiving 2 L/min of 100% oxygen by nasal cannula. She was
transferred to the neonatal intensive care unit for further
management.
In the intensive care unit, umbilical arterial and venous
lines were placed for serial blood gas and central venous
pressure monitoring. iNO was started at 20 ppm through a
nasal cannula with 2 L/min flow. The inspired oxygen was
weaned down to 40% after initiation of iNO.Her first bloodgas
after iNO was started revealed a pH of 7.39 with a Po2 of
68 mm Hg and a pCO2 of 44 mm Hg on 40% oxygen by nasal
cannula. Episodes of oxygen desaturation were not observed
during therapy with iNO.
Repeat echocardiogram after 24 hours of iNO therapy did
not reveal tricuspid regurgitation. Thereafter, iNO was
weaned by 5 ppm every 4 hours per unit protocol for
PPHN. After the first wean from 20 to 15 ppm, the infant
experienced some tachypnea and desaturation, for which she
was placed back on iNO 20 ppm for another 24 hours.
Following this period, she tolerated the iNO wean better
and was off nitric oxide by day 4 of life. Repeat echocardio-
gram done prior to discharge and after being off iNO for
24 hours showed trace tricuspid regurgitation (estimated
right ventricular systolic pressure 25 to 30mmHg). No patent
ductus arteriosus was visualized, and there was good left
ventricular function. She was discharged home with close
cardiology follow-up. Repeat echocardiogram 1 month after
discharge revealed no tricuspid regurgitation and no PDA,
with normal cardiac function. The baby herself was asymp-
tomatic in room air and growing well.
The etiology of pulmonary hypertension resulting in tri-
cuspid regurgitation in this baby was not clear but could be
secondary to antenatal ductal closure resulting in PPHN from
vascular remodeling.8
Discussion
Barotrauma and volutrauma are often associated with pro-
longed mechanical ventilation in newborn infants.9,10 In this
case report, we describe an infant with idiopathic PPHN
successfully treated with iNO, avoiding the hazards of me-
chanical ventilation. To our knowledge, this is the first report
of using iNO by nasal cannula as primary therapy for PPHN in
the immediate newborn period. Noninvasive methods of
delivering iNO have been anecdotally described in the litera-
ture. The fact that iNO can be delivered effectively by contin-
uous flow nasal cannulae was first demonstrated in a young
infant with primary pulmonary hypertension, who was
treated with nasal nitric oxide for several weeks until ap-
proved for enrollment into the long-term intravenous pros-
tacyclin therapy program.11 iNO via a nasopharyngeal tube
was used in a 145-day-old infant with a severely hypoplastic
lung and end-stage pulmonary hypertension, in whom clini-
cal improvement was maintained for 7 days.12 Use of pulsed
Figure 1 Chest radiograph showing clear lung fields without any evidence of parenchymal lung disease suggestive of idiopathic persistent
pulmonary hypertension of the newborn or “black lung disease.”
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nasal delivery of nitric oxide was described in adults with
primary pulmonary hypertension in the home setting.13
Premature infants received iNO therapy through continuous
positive airway pressure and nasal cannula in the weaning
phase in the Nitric Oxide to Prevent Chronic Lung Disease
(NO-CLD) trial for prevention of bronchopulmonary dyspla-
sia without any negative consequences.14 Noninvasive de-
livery of iNO therapy has also been reported for late
pulmonary hypertension in newborn infants with congeni-
tal diaphragmatic hernia. In a case series, patients who had
suprasystemic pulmonary hypertension when iNO was dis-
continued before extubation were treated with iNO through
a nasal cannula. In the same study, nasopharyngeal nitric
oxide concentrations were 5.4  0.5 ppm and 2.4  0.4 ppm
with iNO measured proximally in the delivery device at 10
and 5 ppm, respectively.7 In another case series, the tracheal
concentration of nitric oxide was measured using a chemi-
luminescence device during pulsed nasal nitric oxide deliv-
ery at 20, 40, and 60 mL/breath and found to range between
28 and 38 ppm.15
The feasibility of nitric oxide administration by oxygen
hood in neonatal pulmonary hypertension has been studied
in piglets.16 It was found that nitric oxide decreased (>50%)
pulmonary artery pressure and vascular resistance in both
hypoxia- and Group B streptococcus–induced pulmonary
hypertension, with minimal effects on systemic arterial pres-
sure and cardiac output.
A masked randomized controlled pilot trial using iNO via
oxygen hood was conducted in >34-weeks gestational age
infants with high A–a gradient (400 to 600 mm Hg) with the
primary outcomemeasure being partial pressure of oxygen in
the alveoli an hour after starting study gas. This study did not
complete enrollment but the authors concluded that admin-
istration of iNO byoxygen hood is feasible, but required larger
controlled trials.17
Our patient had symptomatic pulmonary hypertension as
demonstrated by her labile hypoxemia. Echocardiogram sup-
ported this diagnosis and ruled out structural heart disease.
With adequate respiratory drive, no evidence of parenchymal
lung disease on the chest radiograph, and no signs of respira-
tory distress except for mild tachypnea, we felt she did not
warrant intubation and mechanical ventilation, which is
associated with chronic lung injury. iNO was delivered
through the INOmax DS (Ikaria Inc., Hampton, NJ) with the
circuit as shown in the product manual. Though we did not
measure environmental nitric oxide levels, previous studies
have shown negligible leakage of iNO with noninvasive
methods of delivery.12,16,17
Figure 2 Echocardiography revealing a tricuspid regurgitation jet indicative of moderate pulmonary hypertension in the upper frames. On
inhaled nitric oxide, the right ventricular pressures are seen to decrease in the lower frames.
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We conclude that in newborn infants presenting with
hypoxic repiratory failure with hypoxemia without hyper-
carbia, respiratory distress, or evidence of parenchymal lung
disease, therapy with iNO using a nasal cannula may reduce
exposure to high levels of inspired oxygen and avoid me-
chanical ventilation. Randomized and double blinded trials
evaluating this therapeutic modality are warranted.
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